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Background: The concentration of urinary oxalate is more influential to the formation of calcium oxalate urolithiasis
than is urinary calcium concentration. YvrK gene encodes a 43 KD-sized oxalate decarboxylase. We previously
developed the recombinant Escherichia coli (E. coli) expressing Yvrk gene from Bacillus subtilis and named it as
pBy. The aim of this study was to purify the recombinant oxalate decarboxylase overexpressed in E. coli and
evaluate the oxalate-degrading activity of the purified enzyme.
Results: The oxalate-degrading activity of pBy was highest when cultured at pH 5. The activity of purified oxalate
decarboxylase was determined after incubation with sodium oxalate and the optimal pH and temperature of
oxalate decarboxylase were determined. Purified oxalate decarboxylase degraded more than 50% of oxalate
when incubated with MnCl2 and sodium oxalate in atmospheric O2. The optimal pH of recombinant oxalate
decarboxylase was 5 and the optimal temperature was 28°C. Eight-week-old Sprague–Dawley male rats were
used as a transient hyperoxaluric rat model. Suprapubic catheter was inserted into the bladder of each rat and
urine was collected hourly before and 3 hours after oral oxalate intake in the absence and presence of homogenates
of pBy and non-recombinant E. coli as the control. After the oral intake of sodium oxalate, the concentration of oxalate
in urine increased exponentially for 3 hours. The oxalate concentration in urine was decreased significantly by pBy
homogenates compared to control.
Conclusions: We constructed the recombinant E. coli expressing YvrK gene and purified the recombinant oxalate
decarboxylase successfully. Purified recombinant oxalate decarboxylase, as well as recombinant E. coli named pBy,
showed the oxalate-degrading activity in in vitro and in vivo model.
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Studies of the pathophysiology of urinary stones have
focused on oxalate, since the concentration of urinary
oxalate is more influential to the formation of calcium
oxalate urolithiasis than is urinary calcium concentration
[1]. Oxalate is the end product of a metabolic process;
the compound is excreted into the urine. The majority of
urinary oxalate is derived from the endogenous metabol-
ism of glycine, glyoxylate, and ascorbic acid, and 40-50% is* Correspondence: hhkim@snu.ac.kr
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unless otherwise stated.derived from oral ingestion [2]. Hyperoxaluria is induced
by the increased production of oxalate through an abnor-
mal endogenous metabolism or by elevated intestinal
absorption of oxalate [3,4]. Practically, it is difficult to
control the endogenous metabolism of oxalate compared
to the intestinal absorption of oxalate and some studies
have sought to reduce intestinal absorption of oxalate.
Oxalobacter formigenes is an oxalate degrading bacterium
colonizing the gastrointestinal tract of vertebrates including
humans. The bacterium has a symbiotic relationship with
its host by regulating oxalic acid absorption in the intestine
and oxalate levels in plasma and urine [5,6]. Decreased
intestinal colonization of O. formigenes has been re-
ported in recurrent calcium oxalate stone formers and
patients with enteric hyperoxaluria [7,8]. The absence. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Expression level of OXDC after incubation of E. coli
TOP 10 and pBy cells with L-arabinose and MnCl2. The cloned
DNA encoding OXDC was inserted into the pBAD/gIII-A vector and
the plasmid vector transformed into E. coli TOP 10. Expression of
OXDC was induced by different concentration of L-arabinose (0%,
0.02%, 0.2%, 2%, 20%) and MnCl2 and was confirmed using SDS-PAGE
followed by staining with 0.1% Brilliant Blue R.
Lee et al. BMC Research Notes 2014, 7:598 Page 2 of 7
http://www.biomedcentral.com/1756-0500/7/598of O. formigenes has been proposed as a risk factor for
urolithiasis. However, O. formigenes is difficult to cul-
ture and isolate, and has complex pathways of oxalate
degradation.
Recently, the entire DNA sequence of Bacillus subtilis
(B. subtilis) has been determined, which revealed the
existence of a gene designated YvrK gene that encodes a
43 KD-sized oxalate decarboxylase (OXDC). The OXDC
degrades oxalate by a simple pathway [9,10]. Previously
we produced a Yvrk gene-recombinant Escherichia coli
(E. coli) designated pBy, which expresses OXDC, and
evaluated oxalate-degrading activity of the bacteria [11].
The aim of the present study was to purify the recombin-
ant OXDC and evaluate the oxalate-degrading activity of
purified OXDC, with the goal of developing a new treat-
ment for hyperoxaluria in urinary stone patients.
Methods
Production of Yvrk-recombinant E. coli
The Yvrk gene-recombinant E. coli was produced as
described previously [11]. B. subtilis strain 128 obtained
from the Korean Gene Bank was cultured for 24 hours
in Luria-Bertani (LB) broth (Difco, USA) in an aerobic
environment of 95% O2/5% CO2 and temperature of
37°C. Cells were recovered by centrifugation at 5,000 × g
at 4°C for 15 minutes. DNA was extracted from the cell
pellet using a QIAamp DNA mini kit (Qiagen, USA).
The open reading frames and associated ribosome
binding sites of B. subtilis 168 YvrK (GenBank™ accession
no. 2832786) were amplified by polymerase chain reaction
(PCR) using genomic DNA with the following oligonucle-
otides (shown 5′-3′): Yvrk-F, ATGAAAAAAC AAAATG
ACAT TCCG and Yvrk-R, TTTACTG CATTTCTTTT
TCACTAC. The PCR products containing YvrK were
digested with NcoI and SalI. The optimal reaction profile
proved to be 94°C for 5 minutes, followed by 30 cycles of
94°C for 30 seconds for denaturation, 58°C for 30 seconds
and 72°C for 30 seconds for annealing, and 72°C for
5 minute for primer extension. The PCR products were
separated by gel electrophoresis in 2% agarose containing
ethidium bromide, illuminated with ultraviolet light, and
photographed for documentation.
The cloned Yvrk DNA segment was inserted into a
pBAD/gIII-A vector containing a histidine tag. The DNA
sequencing of the Yvrk-recombinant vector was done using
an automated DNA sequencer (ABI Prism®, USA). The
recombinant vector was transfected to non-pathogenic
TOP 10 E. coli with a heat shock method involving 42°C
for 90 seconds followed by 4°C for 10 minutes. The
recombinant E. coli were cultured and selected in LB
agar including ampicillin (100 μg/ml) at 37°C and 95%
O2/5% CO2 for 24 hours.
pBy was grown at 37°C until an OD600 value of 0.5
with shaking. After heat-shocking at 42°C for 2 minutes[12], 5 μl/ml of serial dilution of L-arabinose (Invitrogen,
USA; 0.02%, 0.2%, 2%, 20%) and 5 mM MnCl2 (Sigma-
Aldrich, USA) were added. The cells were incubated at
37°C for 6 hours with shaking and harvested by centri-
fugation (13000 rpm, 10 minutes, 4°C) and stored at
-80°C. Cells containing the empty vector were compared
as negative control. The cell pellet was mixed with so-
dium dodecyl sulfate (SDS) sample buffer and visualized
by 0.1% Brilliant Blue R (Sigma-Aldrich, USA) staining
after separating by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE).
Purification and characterization of recombinant enzyme
pBy cells were grown at 37°C until an OD600 value of 0.3
with shaking. After heat-shocking at 42°C for 2 minutes,
5 μl/ml of 2% L-arabinose and 5 mM MnCl2 were added.
To increase the solubility of OXDC, the cells were incu-
bated at 28°C for 24 hours and centrifuged. The cell pellet
was stored at -80°C.
For purification under native conditions the cells pellet
was thawed for 15 minutes and suspended in lysis buffer
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole,
pH 8.0). Cells were incubated on ice for 30 minutes,
after which lysozyme was added to 1 mg/ml. The solution
was sonicated on ice and the cell lysate was centrifuged at
10,000 × g for 30 min at 4°C. Ni-NTA Superflow (Qiagen,
USA) was added to cleared lysate and mixed gently
by shaking (200 rpm on a rotary shaker) at 4°C for
60 minutes. The lysate-Ni-NTA mixture was loaded
into a column (BioRad, USA) and washed twice with
wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM
imidazole, pH 8.0), and the protein was eluted with
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM
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were mixed with SDS sample buffer and evaluated by
SDS-PAGE.
To determine the optimal pH and temperature, purified
OXDC or PBS in pH 5, pH 6, or pH 7 was incubated with
5 mM MnCl2 and 1.5 mM sodium oxalate for 24 hours
at 10°C, 20°C, 28°C, 37°C, 42°C, 60°C, or 70°C in at-
mospheric O2. The oxalate-degrading activity of puri-
fied OXDC protein was measured using an oxalate kit
(Trinity Biotech, USA).
In vivo oxalate-degrading activity
This study was approved by the Institutional Animal
Care and Use Committee at Seoul National UniversityFigure 2 Measurement of enzyme activity in E. coli TOP 10 and pBy cell
with L-arabinose, MnCl2, and sodium oxalate at pH 5, pH 6, or pH 7 and the o
by an oxalate kit. Cells were incubated for 16 hours (A) and 24 hours (B).Hospital Biomedical Research Institute. A transient hyper-
oxaluric rat model was established using 8-week-old
Sprague–Dawley male rats [13]. Rats were anesthetized
with an intramuscular injection of an 8:2 mixture of keta-
mine (Yuhan, Korea) and rompun (Bayer, Germany). A
midline laparotomy was performed and a p10 tube was
inserted into the bladder. Urine was collected hourly
through the p10 tube before and until 3 hours after oral
oxalate intake together with homogenates of pBy and
TOP 10 E. coli (control). For oral oxalate intake, 0.5 ml of
1 mM sodium oxalate solution and 0.5 ml of pBy homoge-
nates was administered through gastric gavage. Oxalate
concentration in the hourly-collected urine was measured
by a commercial oxalate kit.s at pH 5, pH 6 or pH 7. E. coli TOP 10 and pBy cells were incubated
xalate-degrading activity of OXDC in the supernatants was determined
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Production of Yvrk-recombinant E. coli
As we previously reported [11], 1.2 kb sized Yvrk gene
was cloned from genomic DNA of B. subtilis by PCR.
The Yvrk gene DNA were inserted into the pBAD/gIII-A
vector. Automated DNA sequencing identified the same
DNA sequence of Yvrk gene-recombinant pBAD/gIII-A
vector to that of the Yvrk gene registered in National
Center for Biotechnology Information. Figure 1 showed
that the expression of OXDC was induced by treatment
with L-arabinose in a dose-dependent manner. E. coli
TOP 10 or pBy cells were grown in pH 5, pH 6 or pH 7
LB medium. When the cultures reached OD600 of 0.05,
they were heat-shocked and incubated with L-arabinose,
MnCl2 and sodium oxalate for 16 hours or 24 hours. LB
medium was also incubated and used as control. The
oxalate-degrading activity of pBy was determined by meas-
urement of remaining oxalate. After incubation, amount of
oxalate was not changed in E. coli TOP 10 at pH 5, 6 or
7 (Figure 2A). However, pBy showed oxalate-degrading
activity which was dependent on pH and high in acidic
condition (Figure 2B).
Purification and characterization of recombinant enzyme
The protein obtained as the purified enzyme was analyzed
by SDS-PAGE. The molecular mass was 43 kDa (Figure 3).
We found trace amounts of additional protein bands in
this lane that might be partly host proteins and partly
OXDC degradation products. To measure the activityFigure 3 Purification of recombinant OXDC by affinity
chromatography and evaluation of the purity of recombinant
proteins by SDS-PAGE. The pBy cells were incubated with
L-arabinose and MnCl2. After 6 hours of incubation, cells were harvested
and purified using the Ni–NTA Superflow technique. The purity of
recombinant proteins was determined by SDS-PAGE. M: markers; L:
lysates; W1 & W2: first and second wash; E: elutes.of purified enzyme, purified OXDC or PBS at pH 5 was
incubated with MnCl2 and sodium oxalate for 5 minutes
or 24 hours at room temperature in atmospheric O2. After
incubation, oxalate-degrading activity of enzyme was
measured. As shown in Figure 4A, oxalate was slightly
degraded by OXDC 5 minutes later. After incubation
for 24 hours, significantly reduced oxalate was evident
(Figure 4B). To characterize the OXDC, specific activity
of the purified protein from pBy was measured at pH 5,
6 or 7 and various temperatures after incubation with
MnCl2 and sodium oxalate for 24 hours. The optimal
pH of OXDC was determined over the pH range of 5 to 7,
in pH 1 intervals. At pH 5, the oxalate-degrading activity
was the highest at 28°C and 37°C and the more it was in-
cubated in acidic LB medium, the higher enzyme activity
was (Figure 5A, B). At other temperatures, measurement
of enzyme activity at pH 5-7 also was found similar results
(data not shown). The optimal temperature of OXDC was
investigated over the temperature range 10°C to 70°C. The
highest activities at pH 5 (Figure 5C), pH 6 and pH 7 (data
not shown) were at 28°C.
In vivo oxalate-degrading activity
pBy homogenates reduced urinary oxalate concentration
significantly compared to E.coli TOP 10 in the transient
hyperoxaluric rat model. The urinary oxalate concentra-
tion increased linearly at 1, 2, and 3 hours after gastric
loading of 1 mM of sodium oxalate into rats (Figure 6).
Discussion
Several human diseases have been linked to the excessive
excretion of urinary oxalate. Mild forms of hyperoxaluria
can lead to kidney stones. Kidney stone formation is a
common urological disorder in the U.S. of nearly 13% in
men and 7% in women. Recurrence of stone formation
is common [14]. Larger amounts of oxalate in the urine
can be caused by over-absorption of oxalic acid due
to intestinal diseases. O. formigenes, degrades oxalate
and maintains an important symbiotic relationship
with its hosts by regulating oxalic acid absorption in
the intestine [5].
B. subtilis is a Gram-positive, bacterium commonly
found in soil. B. subtilis is rod-shaped endospore forming
bacterium, which can tolerate extreme environment. A
whole genome analysis of B. subtilis has revealed approxi-
mately 4,100 genes. Of these, 192 are indispensable and 79
are essential. B. subtilis harbors four bicupin-encoding
genes: YvrK, YoaN, YxaG and YwfC. YvrK and YoaN
encode OXDC and YxaG encodes quercetin dioxygenase
[10]. The Yvrk gene has been identified in B. subtilis [9]
and the produced OXDC degrades oxalate in a simple
pathway.
However, B. subtilis does not express the Yvrk gene
during growth in normal conditions and does not use
Figure 5 Effect of pH and temperature on the oxalate-degrading
activity. Purified OXDC was incubated with oxalate at pH 5, 6 or 7 and
enzyme activity of purified OXDC was determined by oxalate kit to
investigate the optimal pH and temperature. Enzyme activity of
purified OXDC (pH 5, pH 6 or pH 7) was measured at 28°C (A) or 37°C
(B). To investigate the optimal temperature, enzyme activity of purified
OXDC at pH 5 was determined at 10°C, 20°C, 28°C, 37°C, 42°C, 60°C,
or 70°C (C).
Figure 4 Measurement of the oxalate-degrading activity of
purified OXDC. Expression of OXDC was induced by the addition
of L-arabinose and MnCl2. After purification, the purified OXDC
was incubated with sodium oxalate at room temperature and
then enzymatic activity of purified OXDC was determined by
oxalate kit. (A) The purified OXDC was incubated with sodium
oxalate for 5 minutes. (B) The purified OXDC was incubated with
sodium oxalate for 24 hours.
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degrades oxalate by a metabolism to maintain its life.
B. subtilis expresses Yvrk in the acidic condition when
it forms endospores. Therefore, we did not manage B.
subtilis directly in the experiment to control oxalate
and produced Yvrk-recombinant E. coli (pBy) capable
of degrading oxalate [11]. Our results show that YvrK
gene from B. subtilis was successfully overexpressed inE. coli when pBy was incubated in the presence of
manganese and oxygen, and the purified recombinant
OXDC, as well as recombinant E. coli named pBy, had
the oxalate-degrading activity. These results suggest that
recombinant OXDC may be used for the treatment of
human hyperoxaluria and prevent calcium oxalate nephro-
calcinosis and urolithiasis.
The oxalate-degrading activity of pBy and recombinant
OXDC in acidic conditions may be limited clinically
because the main oxalate absorbing regions in humans are
known the ileum and colon, whose pH is about 7. In this
Figure 6 In vivo functional assay of pBy homogenate using hyperoxaluric rat model. The oral intake of pBy homogenate reduced hyperoxaluria
compared to control (E coli TOP 10).
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OXDC to degrade oxalate was reduced at near-neutral.
However, some studies reported that stomach is also one
of main places for oxalate absorption to be absorbed in
human above ileum and colon [15-17]. One study evalu-
ated six adult patients on permanent gastric tube feeding
for various reasons, and reported a linear increase in the
urinary oxalate excretion with increased gastric loading
time [17]. The authors concluded that the stomach is not
only just another oxalate absorption site but seems to be
the critical site for intestinal oxalate absorption in an in-
tact gastrointestinal tract.
We developed a transient hyperoxaluric rat model dupli-
cating the performance of this prior study. Since we use rat
models, we collected urine using a suprapubic catheter.
The urinary oxalate concentration increased linearly at 1, 2,
and 3 hours after gastric loading of oxalate into rats, similar
to the previous findings with human patients [17]. When
pBy homogenate was fed together with oxalate loading, the
urinary oxalate concentration decreased compared to con-
trol. The results indicate that pBy homogenate acts in the
stomach of rats and degrades oxalate in vivo. Although
using pBy homogenate for in vivo functional assay is ac-
ceptable for providing preliminary evidence, it is probably
more preferred to use purified enzyme, since purified en-
zyme will be free from contaminants and antigens of host
cells, which otherwise may be present in the crude extract.
Our next plan is to reveal that purified recombinant OXDC
can reduce urinary oxalate concentration and inhibit stone
formation in stone-forming rat models.
Conclusions
In conclusion, we constructed a recombinant E. coli
expressing the YvrK gene and purified the recombinantOXDC successfully. The purified enzyme, as well as
the recombinant E. coli named pBy, showed the oxalate-
degrading activity in in vitro and in vivo model. These data
suggest that recombinant OXDC will provide a solution
in the treatment of calcium oxalate stone and hyperoxa-
luria, which presently lack treatment modalities.
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